Senior Correspondent, London
Ben's Feed
Aug 15, 2014
Aug 15, 2014
Aug 14, 2014

UK cost body backs pricey Gilead hepatitis pill for some patients

LONDON, Aug 15 (Reuters) – Gilead Sciences’
expensive new hepatitis C pill has been endorsed for use in
certain patients by Britain’s healthcare cost-effectiveness
watchdog, after the U.S. firm provided more information.

The National Institute for Health and Care Excellence (NICE)
had told Gilead in June to come back with more data to support
the use of Sovaldi, a drug whose sky-high U.S. price of $1,000
per pill has sparked fierce debate over costly modern medicines.

Aug 13, 2014
Aug 13, 2014
Aug 12, 2014

WHO hopes for more Ebola drug doses, vaccine progress by end of year

LONDON (Reuters) – World Health Organization experts fighting the world’s worst outbreak of Ebola hope for improved supplies of experimental treatments and progress with a vaccine by the end of the year.

That may come too late to put an end to the current epidemic, which is more likely to be stopped by standard infection control measures, but it offers hope for the next inevitable outbreak.

Aug 11, 2014

Exclusive: GlaxoSmithKline faces fresh drug bribery claims in Syria

LONDON (Reuters) – GlaxoSmithKline faces new allegations that it bribed Syrian doctors and officials to boost sales of its medicines, following recent accusations of corruption in its non-prescription business in the country.

The latest charges are laid out in an anonymous email sent to the company’s top managers last week and seen by Reuters.

Aug 11, 2014
Aug 11, 2014

Sanofi bets on inhaled insulin with MannKind deal

PARIS/LONDON, Aug 11 (Reuters) – French drugmaker Sanofi
is betting on inhaled insulin as an alternative option
to daily injections for diabetics by signing a worldwide
licensing agreement with MannKind Corp worth up to $925
million.

Inhalation promises people with diabetes much greater
convenience than routine injections but it remains unclear how
widely it will be adopted, given concerns about the potential
risks associated with breathing powdered insulin into the lungs.

Aug 11, 2014

Sanofi bets on inhaled insulin with up to $925 million MannKind deal

PARIS/LONDON (Reuters) – French drugmaker Sanofi (SASY.PA: Quote, Profile, Research) is betting on inhaled insulin as an alternative option to daily injections for diabetics by signing a worldwide licensing agreement with MannKind Corp (MNKD.O: Quote, Profile, Research) worth up to $925 million (551.02 million British pound).

Inhalation promises people with diabetes much greater convenience than routine injections but it remains unclear how widely it will be adopted, given concerns about the potential risks associated with breathing powdered insulin into the lungs.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben